BioAtla Analyst Ratings
BioAtla Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | 682.12% | JP Morgan | $17 → $14 | Maintains | Overweight |
| 08/02/2023 | 849.72% | JP Morgan | $19 → $17 | Maintains | Overweight |
| 08/02/2023 | 570.39% | JMP Securities | → $12 | Reiterates | Market Outperform → Market Outperform |
| 08/02/2023 | 1296.65% | EF Hutton | → $25 | Reiterates | Buy → Buy |
| 08/02/2023 | 849.72% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 05/15/2023 | 570.39% | JMP Securities | $12 → $12 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 849.72% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 05/12/2023 | 1296.65% | EF Hutton | → $25 | Reiterates | Buy → Buy |
| 04/17/2023 | 1296.65% | EF Hutton | → $25 | Maintains | Buy |
| 04/03/2023 | 961.45% | JP Morgan | $23 → $19 | Maintains | Overweight |
| 03/28/2023 | 626.26% | BTIG | $68 → $13 | Maintains | Buy |
| 03/27/2023 | 570.39% | JMP Securities | $17 → $12 | Maintains | Outperform |
| 03/24/2023 | 346.93% | Credit Suisse | → $8 | Reiterates | → Neutral |
| 03/24/2023 | 1296.65% | EF Hutton | → $25 | Reiterates | → Buy |
| 03/24/2023 | 849.72% | HC Wainwright & Co. | $20 → $17 | Maintains | Buy |
| 01/05/2023 | 1296.65% | EF Hutton | → $25 | Initiates Coverage On | → Buy |
| 11/04/2022 | 346.93% | Credit Suisse | $4 → $8 | Maintains | Neutral |
| 09/15/2022 | 849.72% | JMP Securities | → $17 | Initiates Coverage On | → Market Outperform |
| 08/10/2022 | 123.46% | Credit Suisse | $5 → $4 | Maintains | Neutral |
| 08/10/2022 | 1017.32% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 05/05/2022 | 179.33% | Credit Suisse | $35 → $5 | Downgrades | Outperform → Neutral |
| 03/21/2022 | 1296.65% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 06/28/2021 | 4089.94% | Roth Capital | → $75 | Initiates Coverage On | → Buy |
| 03/26/2021 | 4760.34% | BTIG | $47 → $87 | Maintains | Buy |
| 01/11/2021 | 2637.43% | Credit Suisse | → $49 | Initiates Coverage On | → Outperform |
| 01/11/2021 | 2749.16% | Jefferies | → $51 | Initiates Coverage On | → Buy |
| 01/11/2021 | 2413.97% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 01/11/2021 | 2525.7% | BTIG | → $47 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/25/2023 | 682.12% | 摩根大通 | $17→$14 | 維護 | 超重 |
| 08/02/2023 | 849.72% | 摩根大通 | $19→$17 | 維護 | 超重 |
| 08/02/2023 | 570.39% | JMP證券 | →$12 | 重申 | 市場表現優於→市場表現 |
| 08/02/2023 | 1296.65% | EF Hutton | →$25 | 重申 | 購買→購買 |
| 08/02/2023 | 849.72% | HC Wainwright公司 | →$17 | 重申 | 購買→購買 |
| 2023年05月15日 | 570.39% | JMP證券 | $12→$12 | 重申 | 跑贏→跑贏大盤 |
| 2023年05月15日 | 849.72% | HC Wainwright公司 | →$17 | 重申 | 購買→購買 |
| 2023年05月12日 | 1296.65% | EF Hutton | →$25 | 重申 | 購買→購買 |
| 04/17/2023 | 1296.65% | EF Hutton | →$25 | 維護 | 買 |
| 04/03/2023 | 961.45% | 摩根大通 | $23→$19 | 維護 | 超重 |
| 03/28/2023 | 626.26% | BTIG | $68→$13 | 維護 | 買 |
| 03/27/2023 | 570.39% | JMP證券 | $17→$12 | 維護 | 跑贏大盤 |
| 03/24/2023 | 346.93% | 瑞士信貸 | →$8 | 重申 | →中性 |
| 03/24/2023 | 1296.65% | EF Hutton | →$25 | 重申 | →購買 |
| 03/24/2023 | 849.72% | HC Wainwright公司 | $20→$17 | 維護 | 買 |
| 01/05/2023 | 1296.65% | EF Hutton | →$25 | 開始承保 | →購買 |
| 11/04/2022 | 346.93% | 瑞士信貸 | $4→$8 | 維護 | 中性 |
| 09/15/2022 | 849.72% | JMP證券 | →$17 | 開始承保 | →市場跑贏大盤 |
| 2022年08月10日 | 123.46% | 瑞士信貸 | $5→$4 | 維護 | 中性 |
| 2022年08月10日 | 1017.32% | HC Wainwright公司 | $25→$20 | 維護 | 買 |
| 05/05/2022 | 179.33% | 瑞士信貸 | $35→$5 | 評級下調 | 跑贏→中性 |
| 03/21/2022 | 1296.65% | HC Wainwright公司 | →$25 | 開始承保 | →購買 |
| 2021/06/28 | 4089.94% | 羅斯資本 | →$75 | 開始承保 | →購買 |
| 03/26/2021 | 4760.34% | BTIG | $47→$87 | 維護 | 買 |
| 2021/11/01 | 2637.43% | 瑞士信貸 | →$49 | 開始承保 | →跑贏大盤 |
| 2021/11/01 | 2749.16% | 傑富瑞 | →$51 | 開始承保 | →購買 |
| 2021/11/01 | 2413.97% | 摩根大通 | →$45 | 開始承保 | →超重 |
| 2021/11/01 | 2525.7% | BTIG | →$47 | 開始承保 | →購買 |
What is the target price for BioAtla (BCAB)?
BioAtla(BCAB)的目標價格是多少？
The latest price target for BioAtla (NASDAQ: BCAB) was reported by JP Morgan on September 25, 2023. The analyst firm set a price target for $14.00 expecting BCAB to rise to within 12 months (a possible 682.12% upside). 17 analyst firms have reported ratings in the last year.
摩根大通於2023年9月25日報道了BioAtla(納斯達克代碼：BCAB)的最新目標價。這家分析公司將目標價定為14美元，預計支行將在12個月內上漲至12個月內(可能上漲682.12)。過去一年，17家分析公司公佈了評級。
What is the most recent analyst rating for BioAtla (BCAB)?
BioAtla(BCAB)的最新分析師評級是多少？
The latest analyst rating for BioAtla (NASDAQ: BCAB) was provided by JP Morgan, and BioAtla maintained their overweight rating.
對BioAtla(納斯達克代碼：BCAB)的最新分析師評級由摩根大通提供，BioAtla維持其增持評級。
When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?
BioAtla(BCAB)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與BioAtla的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。BioAtla的上一次評級是在2023年9月25日提交的，所以你應該預計下一次評級將在2024年9月25日左右提供。
Is the Analyst Rating BioAtla (BCAB) correct?
分析師對BioAtla的評級正確嗎？
While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $17.00 to $14.00. The current price BioAtla (BCAB) is trading at is $1.79, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的BioAtla(BCAB)評級維持不變，目標價在17.00美元至14.00美元之間。BioAtla目前的交易價格為1.79美元，超出了分析師的預測範圍。